8rx3

Publication Abstract from PubMed

Leukotriene A4 hydrolase (LTA4H) is the final and rate-limiting enzyme in the biosynthesis of pro-inflammatory leukotriene B4 (LTB(4)). Preclinical studies have provided strong evidence that LTA4H is an attractive drug target for the treatment of chronic inflammatory diseases. Here, we describe the transformation of compound 2, a fragment-like hit, into the potent inhibitor of LTA4H 3. Our strategy involved two key steps. First, we aimed to increase the polarity of fragment 2 to improve its drug-likeness, particularly its solubility, while preserving both its promising potency and low molecular weight. Second, we utilized structural information and incorporated a basic amino function, which allowed for the formation of an essential hydrogen bond with Q136 of LTA4H and consequently enhanced the potency. Compound 3 exhibited exceptional selectivity and showed oral efficacy in a KRN passive serum-induced arthritis model in mice. The anticipated human dose to achieve 90% target engagement at the trough concentration was determined to be 40 mg administered once daily.

Structure-Guided Elaboration of a Fragment-Like Hit into an Orally Efficacious Leukotriene A4 Hydrolase Inhibitor.,Thoma G, Miltz W, Srinivas H, Penno CA, Kiffe M, Gajewska M, Klein K, Evans A, Beerli C, Rohn TA J Med Chem. 2024 Mar 28;67(6):5093-5108. doi: 10.1021/acs.jmedchem.4c00290. Epub , 2024 Mar 12. PMID:38476002^[1]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.